AstraZeneca has announced that Brilinta (ticagrelor) is now the preferred treatment for certain heart patients in the US. The American College of Cardiology (ACC), and American Heart Association (AHA), have released a treatment guideline on the duration of dual antiplatelet therapy (DAPT).
This update is the first time the ACC/AHA has recommended Brilinta, over clopidogrel, for patients who have experienced an ST-elevation myocardial infarction. It is also the first US guideline to provide the medical community with insights drawn from the PEGASUS-TIMI 54 trial.
Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca, said: “We are pleased that the ACC/AHA have further recognised the role of Brilinta, across a broad spectrum of ACS.”